Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 30.48

-0.9%

2:19 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gerald Thomas who wrote (73)	4/5/1997 5:16:00 PM
From: Douglas	of 455

Agouron and Viracept are impressive. I hope you bought it when the share price was around $10 in 1994 and held till last year. A handsome profit. I'll probably hold my Procept shares hoping for a miracle. Procept is the only biotechnology stock I currently own. I recently sold my holding in xoma. The rest of my money is in Lockheed Martin and mutual funds (primarily international). I like the concept of a vaginal topical microbicide, but I agree with you that Procept needs to learn something about investor relations. I mailed them a letter and never received a response. I did get someone to answer the telephone, but really didn't say much. I was reviewing the abstracts from the 4th Conference on Retroviruses & Opportunistic Infections(January 22-26, 1997). My objective was to determine what companies/governments made presentations about possible gel candidates. It seems there were two: 1) Centre de Recherche en Infectiologie of Quebec and 2)Gilead Sciences, Inc. Gilead's homepage is: gilead.com A listing of Gilead's products in development shows the drug candidate is Forvade(Cidofovir Gel). They seem to be in Phase I/II.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next